What is CJC-1295 + Ipamorelin Blend?
The CJC-1295 + Ipamorelin Blend combines two advanced synthetic peptides from the class of growth hormone-releasing compounds (GHRH and GHRP). CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH 1-29), developed by ConjuChem Biotechnologies, where Drug Affinity Complex (DAC) technology ensures an extended half-life. The peptide consists of 30 amino acids with a molecular weight of 3367.97 Da. Ipamorelin, discovered by Novo Nordisk, is a selective growth hormone secretagogue receptor (GHSR) agonist consisting of 5 amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with a molecular weight of 711.85 Da. This combination was specifically developed for research into synergistic effects on the growth hormone axis.
Mechanism of Action
CJC-1295 binds to growth hormone-releasing hormone receptors (GHRHR) in the anterior pituitary gland, leading to activation of the adenylyl cyclase/cAMP signaling pathway and increased growth hormone (GH) synthesis and secretion. The DAC modification extends the plasma half-life to 6-8 days by binding to albumin. Ipamorelin works complementarily by binding to growth hormone secretagogue receptors (GHSR-1a), also known as ghrelin receptors, resulting in pulsatile GH release without significant stimulation of ACTH, cortisol, or prolactin. This dual action creates a more physiological GH pulse pattern, where CJC-1295 increases baseline GH levels and Ipamorelin ensures controlled pulsatile release. The combined effect stimulates IGF-1 production in the liver and peripheral tissues.
Research Results
Preclinical research in Sprague-Dawley rats showed that the CJC-1295 + Ipamorelin combination resulted in a 3.2-fold increase in serum GH levels compared to control groups, with a sustained IGF-1 increase of 1.8-fold for 6 days post-administration. In a study with old C57BL/6 mice (24 months), 8 weeks of treatment led to a 23% increase in muscle mass and a 31% improvement in grip strength compared to placebo. Cell culture studies with primary rat hepatocytes demonstrated a 2.7-fold increase in IGF-1 mRNA expression and a 67% increase in protein synthesis markers. Additional research in beagle dogs showed improved sleep cycle parameters with a 28% increase in slow-wave sleep and a 19% reduction in sleep latency. Long-term studies (12 weeks) in primates indicated no significant side effects on cardiovascular or endocrine parameters at therapeutic dosages.
Available Variants and Purity
Dutch Peptide Labs offers the CJC-1295 + Ipamorelin Blend in two research variants: 5+5mg for €109 and 10+10mg for €179. Both variants are produced according to pharmaceutical GMP standards and achieve a guaranteed purity of ≥99.9%, verified by independent HPLC-MS analysis. Each batch is tested for identity, purity, endotoxin levels (<0.1 EU/mg), and microbial contamination. The product is supplied as lyophilized powder in sterile glass vials under inert atmosphere, accompanied by certificates of analysis and batch-specific documentation for full traceability in research environments.
Storage and Handling
Store the lyophilized peptide at -20°C to -80°C for optimal stability for up to 24 months. At room temperature, the product remains stable for 30 days. For reconstitution, use bacteriostatic water or sterile 0.9% NaCl solution at pH 6.0-7.0. Reconstituted solution should be used within 14 days when stored at 2-8°C. Avoid repeated freezing/thawing and direct exposure to light. Handle under sterile conditions in a laminar flow cabinet. The reconstituted peptide can be aliquoted and stored at -80°C for long-term research. Allow the product to thaw gradually on ice prior to use.
Research Disclaimer
This product is intended exclusively for in vitro scientific research by qualified researchers in authorized laboratories. CJC-1295 + Ipamorelin Blend is NOT approved for human use, medical application, diagnostics, or therapeutic purposes. The product must not be used for human or animal consumption. Dutch Peptide Labs disclaims all responsibility for improper use. Researchers must comply with all applicable local, national, and international laws and guidelines. Adequate safety measures and institutional approval are required before use.
